BTIG, Inari
BTIG raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $81 from $71 and keeps a Buy rating on the shares. The firm ...
Jonathan Krinsky, chief market technician at BTIG, joins CNBC's 'The Exchange to discuss his outlook on stocks for 2025, what ...
24/7 Wall St. on MSN2d
Large-Cap Value Stocks Could Rule in 2025: 4 High-Yield Dividend WinnersHere are four large-cap value stocks that growth and income investors may want to consider now. History suggests they will ...
BTIG Research has recently reduced Fiverr International Ltd (FVRR) stock to Neutral rating, as announced on November 4, 2024, according to Finviz. Earlier, on July 2, 2024, UBS had reduced the stock ...
The S&P 500's rally of 1.8% over just the last two sessions is nice, "but not a game changer yet," according to BTIG's technical guru, Jonathan Krinsky. The chart he provides, below, shows the stock ...
BTIG is growing its transition management business and hired a senior executive to help boost business. The firm has hired Daniel Howell as a director who will be based in New York. His job is ...
BTIG Research has recently reduced Beyond Air Inc (XAIR) stock to Neutral rating, as announced on June 25, 2024, according to Finviz. Earlier, on July 28, 2023, Piper Sandler had initiated the stock ...
BTIG analyst Marie Thibault raised the firm’s price target on Boston Scientific (BSX) to $101 from $97 and keeps a Buy rating ...
BTIG's Krinsky noted that while equity markets in the first half of 2024 were fueled mostly by the surge in mega-cap names ...
BTIG Life Sciences and Diagnostic Tools Analyst Massaro holds group dinner meeting with CEO Stueland and CFO Feeley on January 13 at 10:30 am.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback